FRA:SNW - FR0000120578 - Common Stock
Taking everything into account, SNW scores 6 out of 10 in our fundamental rating. SNW was compared to 50 industry peers in the Pharmaceuticals industry. SNW has an excellent profitability rating, but there are some minor concerns on its financial health. SNW has a correct valuation and a medium growth rate. Finally SNW also has an excellent dividend rating. These ratings would make SNW suitable for dividend investing!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 11.05% | ||
ROE | 19.73% | ||
ROIC | 13.84% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 23.59% | ||
PM (TTM) | 20.35% | ||
GM | 71.7% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.21 | ||
Debt/FCF | 2.21 | ||
Altman-Z | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.27 | ||
Quick Ratio | 0.94 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 10.48 | ||
Fwd PE | 9.08 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 19.17 | ||
EV/EBITDA | 10.2 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 4.96% |
FRA:SNW (9/8/2025, 7:00:00 PM)
79.16
-0.34 (-0.43%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 4.96% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 10.48 | ||
Fwd PE | 9.08 | ||
P/S | 2.84 | ||
P/FCF | 19.17 | ||
P/OCF | 16.97 | ||
P/B | 2.76 | ||
P/tB | 20.77 | ||
EV/EBITDA | 10.2 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 11.05% | ||
ROE | 19.73% | ||
ROCE | 16.7% | ||
ROIC | 13.84% | ||
ROICexc | 16.48% | ||
ROICexgc | 66.95% | ||
OM | 23.59% | ||
PM (TTM) | 20.35% | ||
GM | 71.7% | ||
FCFM | 14.83% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.21 | ||
Debt/FCF | 2.21 | ||
Debt/EBITDA | 0.75 | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | 250 | ||
Cash Conversion | 58.05% | ||
Profit Quality | 72.91% | ||
Current Ratio | 1.27 | ||
Quick Ratio | 0.94 | ||
Altman-Z | N/A |